Abstract
The aim of work is the study of antimicrobial activity of composite semisolid dosage forms for differentiated therapy of foot mycosis with 2-mercaptobenzthiazol and chinozol, namely the paste on emulsive base and the ointment on hydrophilic delivery vehicle. Materials and methods . As the objects of investigation, the paste on emulsive base and the ointment on methylcellulose glycerogel, providing optimal releasing of 2-mercaptobenzthiazol and chinozol from the delivery vehicle and also appropriate semisolid dosage forms (placebo) were used. Antimicrobial activity of paste for nails, ointment for external use and their delivery vehicle was determined for Candida albicans fungi by diffusion into agar method. Candida albicans fungi take second place by the frequency of foot mycosis occurrence after dermatophytes and gram-positive ( Staphylococcus aureus ), gram-negaitive ( Pseudomonas aeruginosa ) pathogenic bacteria because of high frequency of mixtinfection joining the foot mycosis. As the references the well-known antimycotic medications which are registered in Ukraine and for enough time have been used in practice of foot mycosis therapy – cream “Clotrimazole 1 %” (Salutas Pharma, Germany), cream “Exoderil 1 %” (GlaxoSmithKline Pharmaceuticals S.A., Poland), ointment “Kanespor 1 %” (Kern Pharma S.L., Spain) were used. Results . It was revealed that investigated pharmacotherapeutic medicines are characterized by high efficacy for above mentioned microflora. Bases of experimental dosage form have a moderate antimycotic and antibacterial activity caused by onycholytics (salicylic and benzoic acids) and keratolytic (carbamide) presence in formulations. In comparative microbiological studies it was established that the experimental paste for onychomycosis therapy, which contains the composition of nonspecific antimycotics and onycholytics, noticeably surpasses one of the most effective medications – ointment “Kanespor” by the area of growth inhibition zone for pathogenic fungi Candida albicans and gram-negaitive bacteria Escherichia coli and Pseudomonas aeruginosa . It was revealed that by the diameter of growth inhibition zone for above mentioned microorganisms the developed ointment surpasses such modern remedies as cream “Clotrimazole 1 %” and cream “Exoderil 1 %”, which are widely used in topical treatment of dermatological mycosis. Conclusions . Obtained results of antimicrobial activity study of composite semisolid dosage forms for differentiated therapy of foot mycosis on the base of combination of 2-mercaptobenzthiazol and chinozol allow to predict their high clinical value and possibility of providing the domestic dermatology with affordable and effective pharmacotherapeutic medicines, creating the real alternative to import products.
Highlights
Antimicrobial activity of paste for nails, ointment for external use and their delivery vehicle was determined for Candida albicans fungi by diffusion into agar method
As the references the well-known antimycotic medications which are registered in Ukraine and for enough time have been used in practice of foot mycosis therapy – cream “Clotrimazole 1 %” (Salutas Pharma, Germany), cream “Exoderil 1 %” (GlaxoSmithKline Pharmaceuticals S.A., Poland), ointment “Kanespor 1 %” (Kern Pharma S.L., Spain) were used
In comparative microbiological studies it was established that the experimental paste for onychomycosis therapy, which contains the composition of nonspecific antimycotics and onycholytics, noticeably surpasses one of the most effective medications – ointment “Kanespor” by the area of growth inhibition zone for pathogenic fungi Candida albicans and gram-negaitive bacteria Escherichia coli and Pseudomonas aeruginosa
Summary
По диаметру зон задержки роста указанных микроорганизмов разработанная мазь для терапии и профилактики микозов кожных покровов стоп, представляющая собой комбинацию 2-меркаптобензтиазола, хинозола и мягкого кератолитика мочевины, превосходит современные лекарственные средства – крем «Клотримазол 1 %» и крем «Экзодерил 1 %», широко использующиеся в топическом лечении грибковых дерматологических инвазий. Під час порівняльних мікробіологічних досліджень встановили: експериментальна паста для терапії оніхомікозів, що містить композицію неспецифічних антимікотичних активних фармацевтичних інгредієнтів і оніхолітиків, за величиною зон затримки росту патогенних грибів Candida albicans і грамнегативних бактерій Escherichia coli і Pseudomonas aeruginosa суттєво перевершує один із найбільш ефективних препаратів – мазь «Канеспор». За діаметром зон затримки росту названих мікроорганізмів розроблена мазь для терапії, профілактики мікозів шкірних покривів стоп, що є комбінацією 2-меркаптобензтіазолу, хінозолу та м’якого кератолітика сечовини, перевершує сучасні лікарські засоби – крем «Клотримазол 1 %» і крем «Екзодерил 1 %», котрі широко використовуються в топічному лікуванні грибкових дерматологічних інвазій
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Current issues in pharmacy and medicine: science and practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.